A respected presence in the pharmaceutical industry, Taunia Markvicka, PharmD, MBA, served as chief commercial officer with Symbiomix Therapeutics, LLC, and oversees commercialization of the bacterial vaginosis drug Solosec. Solosec, was the first and only single dose oral medication for bacterial vaginosis, a leading gynecologic infection which can have serious health risks leading the company to obtain a qualified infectious disease product designation.
Taunia Markvicka directed the launch preparation of a proprietary pharmaceutical product that achieved FDA approval in 2017, and subsequent acquisition by Lupin Pharmaceuticals. She has undertaken extensive market analysis and led communications with strategic partners, with a focus on accelerating pre-launch pathways.
Dr. Markvicka earned her BS in pharmacy at Creighton University in Omaha and receive a doctor of pharmacy from the University of Nebraska Medical Center. She completed her MBA at St. Joseph University in Philadelphia.
In the early 2000s, Dr. Markvicka held responsibilities with The Medicines Company, leading marketing and new product planning for Angiomax and Clevidipine, Watson Pharmaceuticals with sales and marketing roles in Women's Health, Dermatology, Urology, General Products. Her efforts helped define corporate objectives and enabled the firm to optimize profitability and growth in a number of health care areas. Her subsequent accomplishments have included leading the high-profile launch of EXPAREL for Pacira Pharmaceuticals.
Taunia Markvicka has a strong family focus and emphasizes community service with her daughters, who balance high school and college academic achievements with active athletic commitments.
